Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00067314
Status:
COMPLETED
Last Update Posted:
2012-01-18
First Post:
2003-08-15
Brief Title:
Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase II Study Of Intravenous Edotecarin PHA-782615 In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This international study will study how metastatic breast cancer responds to the investigational drug treatment what are the side effects of the investigational drug when given to women with metastatic breast cancer and how often do these side effects occur The study will also analyze how fast investigational drug and its breakdown products are cleared from the blood in these patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None